Pleuroparenchymal fibroelastosis in rheumatoid arthritis-associated interstitial lung disease.

Respir Res · 2022 · PMC9161503 · PMID 35655303

Europe PMC DOI

hedged sentence

0.0570

closest p · 1.1× alpha

0.0570

boldest claim

The sentences

showed a trendp = 0.057so close (0.05 < p ≤ 0.1)

With regard to PPFE severity, patients with extensive PPFE showed a trend towards worse survival (median survival: 6.2 years) than those with limited PPFE (median survival: 8.4 years; p = 0.057) and significantly worse survival than those without PPFE (median survival: 10.4 years; p = 0.029), as shown in Fig. 1 B.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.